Some of the most encouraging data to be read out in the pancreatic cancer space within the last decade came from the PRODIGE 24/CCTG PA.6 trial, said Autumn McRee, MD, as this was the first trial to demonstrate an overall survival (OS) benefit with an adjuvant strategy of intense chemotherapy combinations often used in the metastatic setting.
In the multicenter phase III trial, patients were randomized to receive either 28-day cycles of the standard gemcitabine on days 1, 8, and 15 for 6 cycles (arm A) or modified FOLFIRINOX every 14 days for 12 cycles (arm B). Read more . . .